Assessment of safety and feasibility of non-invasive vagus nerve stimulation for treatment of acute stroke
Vagus Nerve Stimulation
Stroke
Clinical endpoint
DOI:
10.1016/j.brs.2022.10.012
Publication Date:
2022-11-07T17:40:49Z
AUTHORS (37)
ABSTRACT
Non-invasive vagus nerve stimulation (nVNS) using a hand-held stimulator placed on the neck is an FDA-approved treatment for primary headache disorders. The safety of nVNS unknown in stroke patients.To assess and feasibility acute stroke.TR-VENUS (clinicaltrials.gov identifier NCT03733431) was randomized, sham-controlled, open-label, multicenter trial conducted patients with ischemic (IS) or intracerebral hemorrhage (ICH). Patients were randomly assigned to standard-dose nVNS, high-dose sham stimulation. endpoint composite outcome defined as bradycardia reduction mean arterial blood pressure during progression neurological death within 24 h treatment. endpoints proportion eligible subjects receiving 6 symptom onset completing all pre-specified doses. Efficacy assessments included infarct growth from baseline after treatment.Sixty-nine (61 IS, 8 ICH) completed study. achieved 32.0% 47.7% group (p = 0.203). Treatment initiated but two randomized patients. All dosed received 100% prespecified stimulations. A non-significant observed (184.2% vs. 63.3% nVNS; p 0.109).The results this study suggest that may be safe feasible setting stroke. These findings support further development potential
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (22)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....